RE:RE:New video upAlthrough R.Dumoulin doesn't mention BTD approval in the video...
The last Aug12, 2024 Corporate Presentation, seem to have been updated.
Theralase-Corporate-Presentation-08122024.pdf -If you check page 3 and page 22, the BTD approval is still scheduled for 4Q2024.
Just before Christmas would be nice.
wildbird1 wrote: Kayz88 wrote: No mention of BTD. But 75 patients.
https://youtu.be/uHEwr8jx6jo?si=3oHPXc_vZc4Z15LS
Thank's Kayz88..
..
Theralase Technologies CEO Roger DuMoulin-White Provides Update on Bladder Cancer Clinical Study - YouTube To resume the video...
R.Dumoulin said ...
All the other treatments that have been approved by the FDA, and the new treatments coming are all continuous treatments, you have to take these new treatments for up to two years, and all these treatments have a lower CR% than TLT Ruvidar on the long term.
TLT-Ruvidar is the only ''
One and done treatment'' with a superior CR%, that will be available for BCG resistant patients.
The above should make Dr.Lbiati job,negotiating a big Pharma deal much easier.
.